Victory Capital Management
TRVI icon

Victory Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Victory Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,606
Closed -$6K – 3230
2020
Q1 		$6K Buy
+1,606
New +$7.3K ﹤0.01% 3445
2019
Q4 		– Sell
-986
Closed -$4K – 3234
2019
Q3 		$4K Buy
+986
New +$5.36K ﹤0.01% 3520

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BBVA
Banco Bilbao Vizcaya Argentaria Madrid, Spain $14.3B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management's TRVI Position: Q2 2020 in Review

Victory Capital Management sold out of Trevi Therapeutics (TRVI) in Q2 2020, closing a stake of 1,606 shares — an estimated $6K sold.

Victory Capital Management first reported a position in TRVI in Q3 2019 and held it in 2 quarters. The position peaked at $6K in Q1 2020. 16 funds tracked by Wall St. Rank hold TRVI as of Q2 2020.

  • Victory Capital Management reported no remaining Trevi Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 1,606 Trevi Therapeutics shares in Q2 2020, an estimated $6K.
  • Victory Capital Management first reported a position in Trevi Therapeutics in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Trevi Therapeutics position peaked at $6K in Q1 2020.
  • 16 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.